Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

The researchers used fiber photometry systems to detect neurotransmitters, which involved injecting the mice with fluorescent ...

To uncover what drives sexual behavior in animals, researchers studied the brain activity of male mice throughout the series ...

This will be helpful in developing future therapies for disorders such as premature ejaculation, which affects about 20-30 ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 ...

Researchers have studied how dopamine and acetylcholine regulate the progression of sexual behavior in male mice. Their ...